Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Eisai Launches Leqembi, an Alzheimer’s Drug, in China for Early-Stage Disease

publication date: Feb 8, 2024

Japan’s Eisai expects to administer its Alzheimer’s drug Leqembi to 1,500 people in China, with the goal of completing this task by the end of March 2025. Leqembi was approved for use in early-stage Alzheimer’s by China’s NMPA in January. Eisai is Biogen’s partner on Leqembi and other Alzheimer’s therapies. Both companies have stopped promoting another approved Alzheimer’s drug from their partnership, Adulhelm®, which caused brain bleed and offered only marginal efficacy. China is the third country in the world to approve Leqembi, following the US and Japan. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital